 Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Intra-Cellular Therapies flagship product CAPLYTA lumateperone has significant potential across multiple indications including to treat bipolar disorder and schizophrenia. 